Want to Build Better Web Applications, Faster? Here's How.

If your Enterprise builds native apps for each device, the next couple of minutes could save you months if not years. Read on.

SAN FRANCISCO, CALIFORNIA, UNITED STATES, January 31, 2018 /EINPresswire.com/ — Isomorphic Software – provider of the most advanced, most complete HTML5 technology for building Enterprise business applications – described how their SmartClient platform allows development of single codebase web applications that run on any device, dramatically increasing developer productivity.

Isomorphic Software has always provided technology that makes it possible for web application developers to build extremely powerful, cutting-edge solutions that run on standard browsers (no plugins) via their SmartClient platform (see their live showcase). SmartClient provides:

– A zero-install AJAX/HTML5 client engine
– Advanced UI components (e.g. Excel-like grids, multi-dimensional charts, pivot tables, etc.)
– Client-server data binding systems

However, with smartphones, tablets, and other mobile devices now commonplace in Enterprises, development organizations have to design, build, test and maintain applications for the desktop, then repeat these tasks for every operating system (iOS, Windows, Android, etc.) and individual devices (iPhone 6, iPad, etc.). This rapidly becomes unsustainable.

That is why SmartClient from Isomorphic Software makes sense. With advanced features like Adaptive UI, Responsive Layouts, and Intelligent Auto-Fitting, developers can create powerful, beautiful, single codebase web applications that run on any device. Since development needs to be done only once, the overall effort is radically reduced. This drives solutions to market faster, with higher quality, and with a lower development cost. Isomorphic Software’s key to productivity is set to revolutionize development as we know it.

About Isomorphic Software
Isomorphic Software is based in San Francisco and has over a decade of industry leadership, providing technology platforms for building Enterprise web applications. Companies around the world use the SmartClient Platform, including Cisco, Boeing, Toyota, Philips, and Genentech.

Isomorphic Software
(866) 223-4569
email us here

Source: EIN Presswire

Study Shows Ketosis Fights Alzheimer's Disease

Ketosis Strips

An increasing number of studies report that interventions to enhance metabolic health can
alleviate symptoms and reduce brain pathology associated with AD.

PALM BEACH GARDENS, FL, UNITED STATES, January 31, 2018 /EINPresswire.com/ — Despite decades of attempts to develop a medication that cures or prevents Alzheimer's
disease (AD), the most common form of dementia afflicting our aging population, there's
presently no cure for this devastating illness. Emerging research indicates that such a miracle
remedy might already exist, maybe not in the kind of a pill, but as a straightforward dietary
modification. People can check for ketones by using ketosis strips. They are inexpensive and
can be found at the local pharmacy or online at KetoStrips.com.

An increasing number of studies report that interventions to enhance metabolic health can
alleviate symptoms and reduce brain pathology associated with AD. A favorite theory posits
that AD has numerous causes, but their common thread can demand metabolic breakdown.
Indeed, markers of poor metabolic health, like diabetes, inflammation and higher cholesterol,
are significant risk factors for AD.

The same as our muscles, the brain requires energy to function properly. Both neurons and
muscles have the unique capability to metabolize ketones as an alternative fuel source when
sugar is in short supply, for example through fasting or on a low-carbohydrate diet. In the
1920s scientists discovered a high-fat diet boosting ketogenesis controlled epilepsy. Also
ketosis is still one of the very best treatments for the condition. This increased the possibility
that ketones may also be neuroprotective against other diseases that stem from aberrant
neural metabolism, such as AD. Since then, research has confirmed that ketones do in fact
alter brain metabolism in ways that decrease neuropathology and relieve behavioral signs.
People can check for ketones by using ketosis strips. They are inexpensive and can be found
at the local pharmacy or online at KetoStrips.com

Ketones relieve symptoms of Alzheimer's disease

Over the last ten years, several studies have affirmed the clinical value of ketosis in cognitively
impaired patients. At a 2004 study, twenty people with AD or Mild Cognitive Impairment (MCI)
were treated with placebo or medium chain triglycerides, a sort of saturated fat found in
coconut and palm oils that boosts ketone production. The treatment increased ketone levels 90
minutes afterward, and these higher ketone levels corresponded with increased memory
improvements. All these preliminary, short-term findings were followed up five years later in a
bigger and longer-term study of 152 mild AD patients. After 45 days, individuals taking a
ketogenic chemical showed cognitive enhancements relative to a placebo group. But, both
these studies imply that the brain benefits of ketosis may depend on genetics. In the prior
study, medium chain triglycerides improved cognitive functioning only in participants with no
ApoE4 allele, a genetic risk factor for AD. Similarly, in the later study, cognitive improvements
had been more powerful and persisted longer–outside to 90 days–in those without the ApoE4
allele. A new PLOS One analysis confirmed different answers to diet based on genetics in
mice, reporting a high-fat diet lowered brain levels of ApoE only in mice with no ApoE4 gene.

These promising early findings of ketogenic compounds provided hope that dietary
interventions might similarly benefit brain health. A 2012 study tested whether memory could
be improved by simply adopting a low-carbohydrate diet, without the necessity of supplements
used in the prior studies. Of 23 people with MCI, those after an extremely low-carbohydrate
diet for six months showed improved memory in contrast to people on a high-carbohydrate
diet. These memory enhancements correlated with ketone levels, but maybe not with carbs
consumed, insulin levels or body fat, pointing to increased ketogenesis because the probable
reason behind its low carb dieters' cognitive enhancement.

Although ketosis hasn't been rigorously tested in a proper clinical trial, a recent case study
provides compelling proof that ketones might, in fact, hold up in acute clinical cases. A 63-yearold
guy with advanced AD started consuming coconut oil and medium chain triglycerides, both
proven to increase ketone levels. After just 2.5 months, his score on the Mini-Mental State
Exam, a test of global cognitive functioning, improved from a very low 12 to 20 (from a
maximum 30). After two years, his cognitive capacity and daily living functions both improved
and his MRI revealed no additional brain atrophy. After adding a ketone ester supplement to
his dietary regimen, the patient revealed even further improvements in his disposition, selfsufficiency,
and memory. Notably, this man completed the ApoE4 gene; thus, ketosis does
appear to be extremely beneficial for ApoE4 carriers, even if previous studies suggest it's even
more helpful for those without this risk factor.

How ketones protect the brain

Scientists have looked to animal models to better understand how ketosis may protect the
human brain from neurodegeneration. In a mouse model of AD, amounts of beta-amyloid, a
toxic protein that is elevated in AD, were decreased in the brains of mice fed a high-fat/lowcarb
diet compared to those on a standard diet. Latest research helped to clarify the
connection between the metabolic benefits of ketones, lower amyloid, and improved cognitive
functioning. This study tested the effects ketones either in a mouse model of AD and neurons
treated with amyloid. What's more, ketones decreased amyloid levels and obstructed the
formation of pores in cell membranes induced by amyloid, showing that ketones can protect
against cerebral damage linked to amyloid. At length, ketones revived normal synaptic
plasticity and memory performance which were impaired by amyloid.

A prescription for Ketosis

If ketosis would be to become confirmed as an effective treatment for AD, further study is
needed to determine the appropriate method of administration, since high-fat diets, medium
chain triglyceride supplements or ketogenic substances might be differentially effective. Patient
compliance in following a strict diet or taking supplements may also pose potential challenges.
Identifying the minimum effective dose will help establish guidelines for how rigorous a
treatment regimen is necessary. Despite these remaining questions, the compelling support for
the healing potential of ketosis provides hope that a powerful weapon in our struggle against
AD may already exist–and can be as delicious as a spoonful of coconut oil.

Read More

Everett Wilkinson
email us here

Source: EIN Presswire

Rosanne Hanley to give out free dental needs to 3 people

Rosanne Hanley

Rosanne Hanley

Proper dental care is imperative in maintaining a healthy smile.

SARASOTA, FLORIDA, UNITED STATES, January 31, 2018 /EINPresswire.com/ — With the cost of both routine and cosmetic dentistry rising every year, Rosanne Hanley has stepped forward to help.

Social activist Hanley is looking to sponsor a round of dental care for 3 individuals who may otherwise be unable to afford the treatment or care they need.

The Florida-based fundraiser said of the idea, "A healthy, happy smile is worth a thousand words, but it occurred to me recently that not everyone has the luxury of access to quality dental care."

She continued, "Even routine check-ups can be expensive, while corrective and emergency procedures can cost thousands upon thousands of dollars."

By sponsoring three local individuals, keen volleyball player Hanley hopes she can make a real difference to their happiness and well-being.

"I want to literally put a smile on someone's face!" says an excited Hanley.

A recent study of dentistry prices in the US revealed that the national average cost of a dental exam is now $275 without insurance. This includes an oral exam, basic cleaning, and any necessary X-rays. In more expensive areas, the same visit can cost upwards of $500.

Many dental check-ups call for further treatment, which is where costs can really begin to mount.

The same report revealed that on average, a large filling now costs in excess of $170, while a tooth extraction will set a patient back $280.

Meanwhile, a root canal and bridge both cost over $680 on average, while a crown is likely to cost anywhere from $600-$1,200 depending on the material used.

A necessity for many older patients, denture prices start from $420 on average, while dental implants cost from $1,900 per tooth.

Rosanne Hanley appreciates that these costs are out of reach for many people.

"If you're not insured, visiting the dentist can become impossible due to the costs involved," she says.

"I hate the thought of anyone being in pain or otherwise unhappy because they cannot afford even simple attention from a dentist."

Hanley is hopeful that others will follow in her footsteps by sponsoring dental care for people less fortunate in their area.

"It's about giving something back to your local community," says Hanley. "I like to think that if I was in need, my friends and neighbors would reach out with help. That's the mindset I'm trying to foster in people everywhere!"

Eric Ash
Web Presence, LLC
email us here

Source: EIN Presswire

Gold Medal Star Blockchain to use Singular DTV Blockchain Technology Cryptocurrency For Rewards Program

Gold Medal Star Blockchain Free Tokens

Gold Medal Star Blockchain Free Tokens

Gold Medal Star Blockchain Token

Gold Medal Star Blockchain Token

Gold Medal Star Blockchain

Gold Medal Star Blockchain

World’s 1st Fitness Token Blockchain Rollup offers Free Tokens

To get the five (5) Free tokens offered, visit and
subscribe now at http://www.goldmedalstar.com”

— Reynolds, said.

COLUMBUS, OHIO, UNITED STATES, January 31, 2018 /EINPresswire.com/ — A KickIn Crowd, LLC (AKC), formerly a crowdfunding company and holding company, announced plans to unveil it’s new cryptocurrency, Gold Medal Star Token (GOLDMS), a Wellness, Health and Fitness consumer driven rewards program, using the SingularDTV Blockchain platform by giving away five (5) free tokens to all new Gold Medal Star subscribers.

“We’ve created a rollup combination of companies that really encourages fitness through a consumer driven rewards platform that utilizes the same infrastructure and principles of Bitcoin, Litecoin or Ripple,” Tony Reynolds, founder of AKC said. “The tokens are utility tokens, which will be used in a consumer created groups that allocate rewards based on their preferences,” Reynolds said.

“Our tokens are used like the ones at similar to those at Chuck E. Cheese,” Reynolds said. “Our systems allows consumers to create rewards,which can be redeemed by leveraging the decentralized Blockchain-based cryptocurrency.”

The GOLDMS token, created with the Blockchain entertainment studio, SingularDTV’s, platform Tokit.io, can be purchased using Ethereum (ETH) or SNGLS, which showcases the dynamic power of the Ethereum network.

Singular-DTV is a Centrally Organized Distributed Entity (CODE). CODE is a new form of organizational structure developed in partnership with MME, the same legal firm behind the formation of the Ethereum foundation.

We have created a groundbreaking and massive cryptocurrency consumer driven fitness rewards program. The tokens that can be utilized on our own Fulfillment by Amazon (FBA) companies, and in association with our licensing deal with Seen on Screen, TV, Inc (OTC PINK: SONT). or exchanged for our products.

"To get the five (5) Free tokens offered, visit and subscribe now at http://www.goldmedalstar.com," Reynolds said.


Tony Gold
Gold Medal Star Blockchain
email us here

Source: EIN Presswire

Alliance Growers MJ Botany Centre to Supply 300,000 Plantlets per Month


VANCOUVER, BC, CANADA, January 31, 2018 /EINPresswire.com/ — Alliance Growers Corp. (ACG.C) provided a progress report on the development of the Cannabis Botany Centre. In a news release dated December 30, 2017, Alliance Growers announced that it has entered into a binding Letter of Intent with WFS Pharmagreen Inc., and its proposed subsidiary BC New Co, to create a strategic relationship, together with equity participation by Alliance and Pharmagreen, whereby Alliance will acquire a 30% equity interest in Pharmagreen’s subsidiary BC New Co. The execution of this LOI initiated the development of the Cannabis Botany Centre that Alliance and Pharmagreen have been working on for the past year.

Pharmagreen principals have purchased the land required to build the Cannabis Botany Centre East of Mission, BC. The Land will be leased initially to BC New Co. with an option to purchase at or near cost. BC New Co will build and operate the Cannabis Botany Centre to permit the growth and sale of tissue culture plantlets, and storage of strains and nursery plants to wholesale, retail and medical markets.

The development of the Cannabis Botany Centre has been progressing quickly on several key fronts and Alliance Growers is pleased to provide the following updates:

The Fraser Valley Regional District, Electoral Area G, for Deroche has approved the land use on Bell Road, site of the Cannabis Botany Centre for cannabis production and cannabis related business.

Company management has commenced discussions with FORTIS BC to bring natural gas to the location. This will benefit the surrounding community

The hydrological engineering assessment report for the site to be completed this week.

The Cannabis Botany Centre is poised to supply up to 300,000 plantlets per month to cultivators once built and operating at full capacity.

There are numerous expansion capabilities with 25 acres of available land.

Commenting on the development progress of the Cannabis Botany Centre, Dennis Petke, Alliance Growers’ President and CEO, said “Now that Alliance is capitalized, we will be working closely with Pharmagreen to accelerate the development of the Cannabis Botany Centre. The path to approval for an ACMPR license will be expeditious. The development of the Cannabis Botany Centre is consistent with Alliance Growers business plan to be in partnership with a range of cannabis sector business opportunities including strategic investments in ACMPR licensed cannabis producers. Alliance Growers has already acquired interests in two ACMPR applicants, notably Biocannatech, whereby Alliance recently acquired 100% ownership of this late-stage Quebec ACMPR applicant; and Canwe, a private company based in Ontario that has applied for its ACMPR license and is currently in the review and security clearance stage. Alliance continues to negotiate further acquisitions in the grow space in Canada and Australia.

We look forward to announcing new strategic and complementary acquisitions as we move forward. It is an exciting time of progress in the cannabis industry and Alliance is building a diversified global cannabis company that is focused on where the market is going, not where the market is today.”


TSX Penny Stocks
TSX Penny Stocks
email us here

Source: EIN Presswire

ScImage Celebrates 25th Anniversary

LOS ALTOS, CA, UNITED STATES, January 31, 2018 /EINPresswire.com/ — ScImage, Inc., a leading provider of Enterprise PACS solutions, is celebrating 25 years of providing innovative imaging and workflow solutions to the healthcare industry.

Sai Raya, PhD, founded the company in 1993 with private-labeled filmless angiography, 3D intravascular ultrasound and coronary calcium scoring software systems. During the late 1990s, the company pioneered the concept of a patient-centric approach to clinical imaging to eliminate shortcomings of siloed departmental solutions. ScImage introduced PICOM in 2001 with the first ever Cloud-based PACS offering.

“Our steady and organic growth from a 2-person start-up is a direct outcome of our commitment to providing the highest quality imaging products and excellent service to our customers and end-users,” noted Madvi Raya, co-owner and CFO. “Apart from contributing to the medical industry by developing innovative and cost-effective product lines, listening to our customers continues to be our company culture. I am grateful to our employees for retaining our founding values!”

The company’s suite of product offerings has expanded over the years in anticipation of industry changes and customers’ evolving business needs. Picom365.com has become the home for hundreds of institutions for clinical imaging and reporting workflow, secure image exchange for interoperability, and cloud storage for disaster recovery. Over the years, the on-premise PicomEnterprise with its Cloud counterparts, has become a powerful platform to handle end-to-end imaging workflows for most departments within the health enterprise. Native support for waveforms and non-imaging data, ability to handle complex ordering environments and the ability to interface to any possible EHR system are the unique strengths of PICOM365. Specialty based reporting methodologies along with advanced visualization are seamlessly delivered anywhere to highly mobile physicians of the modern imaging practice.

“Over the past 25 years, ScImage has consistently pushed the envelope in enterprise imaging workflow with our characteristic out-of-the-box thinking. Our core belief in one satisfied customer at a time and long-term good relationships with our partners became our investment vehicle to build a solid company with a wealth of intellectual property and with no external investment,” remarked Sai Raya, PhD, Founder and CEO of ScImage, Inc. “It gives me great pride to join our valued employees, customers and partners in celebrating this milestone anniversary.”

Today, hundreds of healthcare institutions of all sizes use PICOM365 on-premise and in the Cloud. ScImage continues to thrive with a customer-centric mindset, focused on delivering customized enterprise imaging solutions that will meet the changing needs of the healthcare IT landscape.

Christie Scherkenbach
ScImage, Inc.
email us here

Source: EIN Presswire

Global Gene Therapy Market Expected to Reach $4,300 Million by 2021: Polaris Market Research

The Rising demand of the personalized treatments and need for the one stop cure for the rare indications and niche segments of the disease has led to the emergence of the gene therapies.”

— Polaris Market Research

BROOKLYN, NY, UNITED STATES, January 31, 2018 /EINPresswire.com/ — The Global Gene Therapy market size is expected to reach USD 4,300 million market by 2021 as reported by Polaris Market Research.

The Rising demand of the personalized treatments and need for the one stop cure for the rare indications and niche segments of the disease has led to the emergence of the gene therapies as a therapy option for the critical and deadly indications. The positive attitude of regulatory bodies has also created a favorable environment for the research and development in these therapies.

As of January 2018, there are 3000+ Reported Clinical Trials for Gene therapies, out of which 500+ trials are currently ongoing. The increase in the government funds for the research and development also paving the way for the secure future of gene therapies in coming time.

Polaris Market Research expects that with the expected launch of the potential gene therapies, the market is expected to rise at a higher pace. The Unites States accounts for the higher share of the market as compared to the Europe and Japan. The highest market size is subjected to the approval of KYMRIAH (Novartis), YESCARTA (Kite Pharmaceuticals) and LUXTURNA (Spark Therapeutics) and associated premium pricing.

Currently the Gene Therapy market is highly fragmented but with the current initiatives taken by the government and fastened approval process in developed countries, the market is soon going to be regulated.

The only restrain to the Gene Therapy market is premium pricing of the therapies. Polaris Market Research believes that the affordability of gene therapy is one of the primary concern in the mature markets. GlaxoSmithKline recently in October 2017 launched the gene therapy, STRIMVELIS for the ultra-rare disorder i.e. Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency (AD-SCID) This drug comes with the price tag of $665,000 which makes it THE expensive drug in the entire gene therapy segment. The drug also comes with money back guarantee as reported by the company itself.

Polaris Market Research has provided the forecasts of the Global Gene Therapy Market from 2016-2021.

The major segments which has been investigated in the global market from 2016-2021 are:

1. Market Analysis by Marketed Gene Therapies
2. Market Analysis by Companies
3. Market Analysis by Indications

The Marketed Therapies undertaken in forecast from 2016-2021 are:

1. Rexin-G (Epeius Biotechnologies Corporation)
2. Gendicine (SiBiono GeneTech Co., Ltd)
3. Neovasculgen [Human Stem Cells Institute (HSCI))
4. Glybera (UniQure Biopharma B.V.)
5. KYMRIAH (Novartis)
6. YESCARTA (Kite Pharmaceuticals)
7. LUXTURNA (Spark Therapeutics)
8. STRIMVELIS (GlaxoSmithKline)

The Major Indications in Gene Therapy are:
1. Cancer
2. Neurodegenerative Disorders
3. Lysosomal Storage Disorders (LSDs)
4. Ocular Diseases
5. Muscle Disorders
6. Anemia
7. Hemophilia
8. Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency

Leading Companies investigated in the Report are

1. Novartis Pharmaceuticals Corporation
2. Kite Pharma, Incorporated
3. Spark Therapeutics, Inc
4. GlaxoSmithKline
5. Adaptimmune
6. Bluebird bio
7. Celgene
8. Shanghai Sunway Biotech
9. Shenzhen SiBiono GeneTech
10. SynerGene Therapeutics
11. Others

Browse other reports by Polaris Market Research:

Polaris Market Research & Consulting
email us here

Source: EIN Presswire

Iodine Global Market 2018: Key Players – SQM, Cosayach, Ise Chemicals, Algorta Norte S.A., Godo Shigen, Iochem

Iodine -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023

PUNE, MAHARASHTRA, INDIA, January 31, 2018 /EINPresswire.com/ — Iodine Industry


Wiseguyreports.Com Adds “Iodine -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023” To Its Research Database

Iodine is, as a commercial product, solid and heavy like metal and has black-purple luster. It easily sublimates at the room temperature and has a peculiar odor.Iodine is widely used in food, medicine, industry, agriculture, national defense, and many other cutting-edge technology industries. 

The global Iodine market will reach xxx Million USD in 2017 and CAGR xx% 2011-2017. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Iodine by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report. 

Company Coverage (Sales Revenue, Price, Gross Margin, Main Products etc.): 

Ise Chemicals 
Algorta Norte S.A. 
Godo Shigen 
Nippoh Chemicals 
RB Energy 
Toho Earthtech 

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/2586720-global-iodine-market-analysis-2011-2017-and-forecast-2018-2023

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.): 
Saltpeter Minera Iodine 
Underground Brine Iodine 
Seaweed Iodine 

Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.): 
X-ray Contrast Media 
Iodophors and PVP-I 
LCD Screens 
Animal Nutrition 

Region Coverage (Regional Output, Demand & Forecast by Countries etc.): 
North America 
South America 
Middle East & Africa

Leave a Query @ https://www.wiseguyreports.com/enquiry/2586720-global-iodine-market-analysis-2011-2017-and-forecast-2018-2023

Table of Content 

1 Industry Overview 
1.1 Iodine Industry 
1.1.1 Overview 
1.1.2 Development of Iodine 
1.2 Market Segment 
1.2.1 Upstream 
1.2.2 Downstream 
1.3 Cost Analysis 
2 Industry Environment 
2.1 Policy 
2.2 Economics 
2.3 Sociology 
2.4 Technology 
3 Iodine Market by Type 
3.1 Segment Overview 
3.1.1 Saltpeter Minera Iodine 
3.1.2 Underground Brine Iodine 
3.1.3 Seaweed Iodine 
3.2 Market Size 
3.3 Market Forecast 
4 Major Companies List 
4.1 SQM (Company Profile, Sales Data etc.) 
4.2 Cosayach (Company Profile, Sales Data etc.) 
4.3 Ise Chemicals (Company Profile, Sales Data etc.) 
4.4 Algorta Norte S.A. (Company Profile, Sales Data etc.) 
4.5 Godo Shigen (Company Profile, Sales Data etc.) 
4.6 Iochem (Company Profile, Sales Data etc.) 
4.7 Nippoh Chemicals (Company Profile, Sales Data etc.) 
4.8 RB Energy (Company Profile, Sales Data etc.) 
4.9 Toho Earthtech (Company Profile, Sales Data etc.) 
4.10 Iofina (Company Profile, Sales Data etc.) 
4.11 Wengfu (Company Profile, Sales Data etc.) 
5 Market Competition 
5.1 Company Competition 
5.2 Regional Market by Company 
6 Market Demand 
6.1 Demand Situation 
6.1.1 Demand in X-ray Contrast Media 
6.1.2 Demand in Pharmaceuticals 
6.1.3 Demand in Iodophors and PVP-I 
6.1.4 Demand in LCD Screens 
6.1.5 Demand in Animal Nutrition 
6.1.6 Demand in Others 
6.2 Regional Demand Comparison 
6.3 Demand Forecast 
7 Region Operation 
7.1 Regional Output 
7.2 Regional Market 
7.3 by Region 
7.3.1 North America Overview by Country (U.S., Canada, Mexico) 
7.3.2 Europe Overview by Country (Germany, U.K., France, Italy, Russia, Spain etc.) 
7.3.3 Asia-Pacific Overview by Country (China, India, Japan, Southeast Asia etc.) 
7.3.4 South America Overview by Country (Brazil, Argentina etc.) 
7.3.5 Middle East & Africa Overview by Country (Saudi Arabia, South Africa etc.) 
7.4 Regional Forecast 
8 Marketing & Price 
8.1 Price and Margin 
8.1.1 Price Trends 
8.1.2 Factors of Price Change 
8.1.3 Manufacturers Gross Margin Analysis 
8.2 Value Chain 
8.3 Marketing Channel 
9 Research Conclusion

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2586720


Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us)  Ph: +44 208 133 9349 (Uk)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here

Source: EIN Presswire

Global Bio-PET Film Market 2018 Industry Analysis, Size, Share, Growth, Trends, Opportunities and Forecast by 2022

WiseGuyReports.com adds “Bio-PET Film Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2022”reports to its database.

PUNE, INDIA, January 31, 2018 /EINPresswire.com/ — Bio-PET Film Market:

Executive Summary

This report studies Bio-PET Film in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering

Mondi Group
SKC Films
M&G Chemicals
Teijssin Limited
Plastipak Holdings

Request Sample Report @ https://www.wiseguyreports.com/sample-request/2848635-global-bio-pet-film-market-professional-survey-report-2018

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Universal Film
Electrical Insulating Film
Capacitor Film
Laminating Film

By Application, the market can be split into

Industrial & Specialties

By Regions, this report covers (we can add the regions/countries as you want)

North America
Southeast Asia

If you have any special requirements, please let us know and we will offer you the report as you want.

For further information on this report, visit – https://www.wiseguyreports.com/enquiry/2848635-global-bio-pet-film-market-professional-survey-report-2018

Table of content:

Global Bio-PET Film Market Professional Survey Report 2017 
1 Industry Overview of Bio-PET Film 
1.1 Definition and Specifications of Bio-PET Film 
1.1.1 Definition of Bio-PET Film 
1.1.2 Specifications of Bio-PET Film 
1.2 Classification of Bio-PET Film 
1.2.1 Universal Film 
1.2.2 Electrical Insulating Film 
1.2.3 Capacitor Film 
1.2.4 Laminating Film 
1.3 Applications of Bio-PET Film 
1.3.1 Packaging 
1.3.2 Industrial & Specialties 
1.3.3 Electrical 
1.3.4 Imaging 
1.4 Market Segment by Regions 
1.4.1 North America 
1.4.2 China 
1.4.3 Europe 
1.4.4 Southeast Asia 
1.4.5 Japan 
1.4.6 India

2 Manufacturing Cost Structure Analysis of Bio-PET Film 
2.1 Raw Material and Suppliers 
2.2 Manufacturing Cost Structure Analysis of Bio-PET Film 
2.3 Manufacturing Process Analysis of Bio-PET Film 
2.4 Industry Chain Structure of Bio-PET Film

3 Technical Data and Manufacturing Plants Analysis of Bio-PET Film 
3.1 Capacity and Commercial Production Date of Global Bio-PET Film Major Manufacturers in 2016 
3.2 Manufacturing Plants Distribution of Global Bio-PET Film Major Manufacturers in 2016 
3.3 R&D Status and Technology Source of Global Bio-PET Film Major Manufacturers in 2016 
3.4 Raw Materials Sources Analysis of Global Bio-PET Film Major Manufacturers in 2016

4 Global Bio-PET Film Overall Market Overview 
4.1 2012-2017E Overall Market Analysis 
4.2 Capacity Analysis 
4.2.1 2012-2017E Global Bio-PET Film Capacity and Growth Rate Analysis 
4.2.2 2016 Bio-PET Film Capacity Analysis (Company Segment) 
4.3 Sales Analysis 
4.3.1 2012-2017E Global Bio-PET Film Sales and Growth Rate Analysis 
4.3.2 2016 Bio-PET Film Sales Analysis (Company Segment) 
4.4 Sales Price Analysis 
4.4.1 2012-2017E Global Bio-PET Film Sales Price 
4.4.2 2016 Bio-PET Film Sales Price Analysis (Company Segment)

5 Bio-PET Film Regional Market Analysis 
5.1 North America Bio-PET Film Market Analysis 
5.1.1 North America Bio-PET Film Market Overview 
5.1.2 North America 2012-2017E Bio-PET Film Local Supply, Import, Export, Local Consumption Analysis 
5.1.3 North America 2012-2017E Bio-PET Film Sales Price Analysis 
5.1.4 North America 2016 Bio-PET Film Market Share Analysis 
5.2 China Bio-PET Film Market Analysis 
5.2.1 China Bio-PET Film Market Overview 
5.2.2 China 2012-2017E Bio-PET Film Local Supply, Import, Export, Local Consumption Analysis 
5.2.3 China 2012-2017E Bio-PET Film Sales Price Analysis 
5.2.4 China 2016 Bio-PET Film Market Share Analysis 
5.3 Europe Bio-PET Film Market Analysis 
5.3.1 Europe Bio-PET Film Market Overview 
5.3.2 Europe 2012-2017E Bio-PET Film Local Supply, Import, Export, Local Consumption Analysis 
5.3.3 Europe 2012-2017E Bio-PET Film Sales Price Analysis 
5.3.4 Europe 2016 Bio-PET Film Market Share Analysis 
5.4 Southeast Asia Bio-PET Film Market Analysis 
5.4.1 Southeast Asia Bio-PET Film Market Overview 
5.4.2 Southeast Asia 2012-2017E Bio-PET Film Local Supply, Import, Export, Local Consumption Analysis 
5.4.3 Southeast Asia 2012-2017E Bio-PET Film Sales Price Analysis 
5.4.4 Southeast Asia 2016 Bio-PET Film Market Share Analysis 
5.5 Japan Bio-PET Film Market Analysis 
5.5.1 Japan Bio-PET Film Market Overview 
5.5.2 Japan 2012-2017E Bio-PET Film Local Supply, Import, Export, Local Consumption Analysis 
5.5.3 Japan 2012-2017E Bio-PET Film Sales Price Analysis 
5.5.4 Japan 2016 Bio-PET Film Market Share Analysis 
5.6 India Bio-PET Film Market Analysis 
5.6.1 India Bio-PET Film Market Overview 
5.6.2 India 2012-2017E Bio-PET Film Local Supply, Import, Export, Local Consumption Analysis 
5.6.3 India 2012-2017E Bio-PET Film Sales Price Analysis 
5.6.4 India 2016 Bio-PET Film Market Share Analysis

6 Global 2012-2017E Bio-PET Film Segment Market Analysis (by Type) 
6.1 Global 2012-2017E Bio-PET Film Sales by Type 
6.2 Different Types of Bio-PET Film Product Interview Price Analysis 
6.3 Different Types of Bio-PET Film Product Driving Factors Analysis 
6.3.1 Universal Film of Bio-PET Film Growth Driving Factor Analysis 
6.3.2 Electrical Insulating Film of Bio-PET Film Growth Driving Factor Analysis 
6.3.3 Capacitor Film of Bio-PET Film Growth Driving Factor Analysis 
6.3.4 Laminating Film of Bio-PET Film Growth Driving Factor Analysis

7 Global 2012-2017E Bio-PET Film Segment Market Analysis (by Application) 
7.1 Global 2012-2017E Bio-PET Film Consumption by Application 
7.2 Different Application of Bio-PET Film Product Interview Price Analysis 
7.3 Different Application of Bio-PET Film Product Driving Factors Analysis 
7.3.1 Packaging of Bio-PET Film Growth Driving Factor Analysis 
7.3.2 Industrial & Specialties of Bio-PET Film Growth Driving Factor Analysis 
7.3.3 Electrical of Bio-PET Film Growth Driving Factor Analysis 
7.3.4 Imaging of Bio-PET Film Growth Driving Factor Analysis


Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=2848635

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here

Source: EIN Presswire


Completes process development for the AGT103-T automated cell manufacturing protocol

ROCKVILLE, MD, USA, January 31, 2018 /EINPresswire.com/ — American Gene Technologies International Inc. (AGT), a leading gene and cell therapy company, today announced completion of the pilot runs of its HIV Functional Cure automated cell processing protocol. This completes a key milestone of AGT’s planned Phase I clinical trial of AGT103-T, a genetically modified autologous T cell product in development as an HIV functional cure.

“This accomplishes the second of two key developments that prepare AGT for an IND submission,” said David Pauza, Ph.D., AGT’s Chief Science Officer. “We have now produced a GMP-grade lentiviral vector stock that will modify HIV-specific T cells to make them immune to HIV entry and depletion. We fully developed the process for treating cells, in an automated unit, which reliably manufactures the cell product. The results from the most recent pilot run were nearly four times the level that we believe is necessary to restore HIV immunity in HIV-positive individuals.”

The devastating impact of HIV/AIDS was dramatically relieved due to the development and global distribution of antiretroviral drugs. While these drugs marked a landmark achievement for medicine, even decades of treatment do not cure HIV and the virus re-emerges within just a few weeks off therapy. AGT103-T is the result of advances in genetic research to develop an immunotherapeutic that will potentially create a functional cure by reconstituting each person’s immunity to HIV disease. The approach taken by AGT differs substantially from other companies’ strategies by focusing on HIV-specific immune cells responsible for building and maintaining strong immunity against the virus. AGT’s product protects these HIV-specific immune cells through genetic modifications that knock down CCR5, a key surface protein utilized by HIV, and prevents replication of HIV already resident in those T cells. AGT’s cell therapy is expected to enable HIV-infected individuals to control and eliminate their viremia over time without the need for lifelong antiretroviral chemotherapy, render them non-contagious, protect them from developing AIDS, and provide immunity to reinfection for life.

Jeff Galvin, Chief Executive Officer, added, “This product is the most complex cell therapy the industry has delivered to date, and is a further indication of the sophistication, depth and breadth of AGT’s gene technology platform for drug development. We hope to show efficacy for our HIV treatment this year and add several infectious disease therapeutics to our pipeline in 2019, while continuing to develop our monogenic disease portfolio and our gamma delta T cell immuno-oncology programs.”

American Gene Technologies

AGT is an emerging gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications including large and orphan indications, infectious disease, immune-oncology, and monogenic disorders. AGT expects to take its lead candidate for an HIV functional cure into the clinic in 2018 and is pioneering a novel immuno-oncology approach of stimulating gamma-delta (γδ) T cells to attack multiple cancers. AGT has a diverse portfolio of patent filings surrounding key tools and components in viral vectors, gene therapy, and regenerative medicine, and a key patent in AGT's novel immuno-oncology approach has already been granted. AGT has developed a modified gene (patent-pending) able to express therapeutic levels of phenylalanine hydroxylase (PAH) that it is deploying, along with other proprietary AGT technologies, in pursuit of a cure for Phenylketonuria (PKU). AGT expects to begin clinical activities for PKU in 2019, and for liver cancer (AGT's first immuno-oncology therapy) in 2020.

More information can be found at www.americangene.com.

American Gene Technologies Contact:
C. Neil Lyons, Chief Financial Officer
Phone: (301) 337-2269
Email: info@americangene.com

Media Contact:
Cari P. Randall, Vice President
The Ruth Group
Phone: (646) 536-7002
Email: crandall@theruthgroup.com

Investor Contact:
Robert E. Flamm, Ph.D., Senior Vice President
The Ruth Group
Phone: (646) 536-7017
Email: rflamm@theruthgroup.com

Sasha Whitaker
American Gene Technologies International Inc.
email us here

Source: EIN Presswire